Streetbeat News

Earnings

MLNK

MillerKnoll's stock is trading lower following mixed Q3 financial results and Q4 guidance for adjusted EPS and revenue that fell short of expectations.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 11:05 am

GILD

XLO

Gilead Sciences, Inc. (GILD) and Xilio Therapeutics (XLO) have entered into an exclusive license agreement for XTX301, a Phase 1 tumor-activated IL-12 program. Gilead will pay Xilio $43.5 million upfront, including $30 million in cash and a $13.5 million equity investment at a premium. Additionally, Xilio could receive up to $604 million in contingent payments based on development, regulatory, and sales milestones. The deal is expected to reduce Gilead's 2024 EPS by $0.03 to $0.04.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 11:04 am

WBA

Walgreens Boots Alliance has updated its fiscal 2024 adjusted EPS guidance to a narrower range of $3.20-$3.35, from the previous range of $3.20-$3.50. This update is slightly above the consensus estimate of $3.24.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 11:03 am

QBTS

D-Wave Quantum, identified by the symbol QBTS, has provided its fiscal year 2024 and Q1 outlook, expecting Q1 bookings of at least $4.3M and an Adjusted EBITDA Loss for fiscal 2024 to be less than the previous year's $54.3 million.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 11:03 am

QBTS

D-Wave Quantum (QBTS) reported Q4 earnings with EPS of $(0.10), meeting analyst estimates, but missed revenue forecasts with $2.91M against an expected $4.73M. Year-over-year, sales increased by 21.08% from $2.40M.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 11:01 am

WBA

Walgreens Boots Alliance (WBA) reported Q2 adjusted EPS of $1.20, surpassing the $0.82 estimate, marking a 46.34% beat and a 3.45% increase from last year's $1.16. However, Q2 sales of $37.05M drastically missed the $35.86B estimate, representing a 99.90% miss and a 99.89% decrease from last year's $34.86B.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 11:01 am

ITRM

Iterum Therapeutics reported its Q4 2023 earnings with a GAAP EPS of $(0.94), meeting the analyst consensus estimate. The company also reported a cash position of $23.9M.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 11:01 am

MTRN

Materion anticipates that the impact of its Q1 shortfall will be compensated for throughout the remainder of 2024. The company remains optimistic about recovering from the early-year financial setback.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 10:54 am

MTRN

Materion Corporation has provided an estimate for its value-added sales for the first quarter, projecting them to be in the range of $255 million to $265 million.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 10:54 am

USAP

Universal Stainless (NASDAQ:USAP) reported Q4 earnings of $0.27 per share, missing the consensus estimate of $0.32 by 15.62%. However, sales of $79.78M exceeded estimates of $78.65M by 1.44%, marking a 41.96% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 10:49 am